Download our whitepaper,
The Complexities of Schizophrenia:
Diagnosis, Management and
Research
What's Inside:
- Key FDA-Approved Pivotal Endpoints for Schizophrenia Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for Schizophrenia.
- Comprehensive Analysis of FDA-Approved Schizophrenia Drugs.
- How Diagnostic Criteria for Schizophrenia Have Evolved and Impact Research.
- Overcoming Common Pitfalls in Schizophrenia Clinical Trials.
- And additional insights to drive your trial’s success.
Access your complimentary whitepaper today:
Schizophrenia Clinical Trials
Schizophrenia is a mental health condition characterized by distorted thinking, perceptions, emotions, language, sense of self, and behavior. It is a serious disorder affecting individuals of all ages and can vary in severity and duration, often requiring long-term management.
Over time, research has advanced from viewing schizophrenia merely as a behavioral issue to understanding its complex mechanisms involving genetic, neurobiological, and environmental factors.
This evolving understanding has been crucial in developing current therapeutic approaches that aim to manage symptoms, improve overall functioning, and address the psychological components of the disorder.
iNGENū’s team of experienced researchers and clinicians specializes in designing and conducting innovative studies. By leveraging enhanced trial design and comprehensive patient-centric strategies, we are committed to accelerating the development of new treatments for schizophrenia.
25%
of people with Schizophrenia recover completely
75%
of people with Schizophrenia show symptom improvement with antipsychotics
25%
increase in treatment efficacy has been observed over the past decade due to ongoing research
Our clinical team has over
120 years
years of combined clinical trial experience